Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification

Tae Kim, Seung; Jang, Hye-Lim; Jin Lee, Su; Lee, Jeeyun; Choi, Yoon‐La; Kim, Kyoung‐Mee; Cho, Jeonghee; Hoon Park, Se; Suk Park, Young; Yeong Lim, Ho; Yashiro, Masakazu; Ki Kang, Won; Oh Park, Joon

doi:10.1158/1535-7163.mct-14-0255

Public

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification

Published in Molecular Cancer Therapeutics • Sep 24, 2014

Authors:

Seung Tae Kim

Hye-Lim Jang

Su Jin Lee

Abstract

Pazopanib is an orally bioavailable, ATP-competitive, multitargeted tyrosine kinase inhibitor mainly targeting VEGFR2 and PDGFR tyrosine kinases, but the biologic sequences of pazopanib activities beyond antiangiogenesis are poorly defined. We used a panel of 38 gastric cancer cell lines to test the...

Subject

Pazopanib

Cancer research

Cell growth

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!